April 12, 2017 (Shareholders Foundation) - An investigation on behalf of investors of LivaNova PLC (NASDAQ:LIVN) shares over potential securities laws violations by LivaNova PLC and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of LivaNova PLC (NASDAQ:LIVN) concerning whether a series of statements by LivaNova PLC regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

London based LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. LivaNova PLC reported that its Total Revenue rose from $291.56 million for the 52 weeks period that ended on April 24, 2015 to over $1.21 billion for the 12 months period that ended on December 31, 2016 and that its Net Income of $57.85 million declined to a Net loss of $62.79 million.

On March 31, 2017, LivaNova PLC announced the resignation of its Chief Financial Officer (CFO), Vivid Sehgal. Sehgal, who has been with LivaNova since the Companys inception in October of 2015, is leaving to pursue other opportunities and will continue as CFO and support an orderly transition to his successor.